INDIANAPOLIS — The FDA has expanded approval of Eli Lilly’s Mounjaro, allowing the diabetes drug to be used to reduce the risk of heart attack, stroke or cardiovascular death in adults with type 2 diabetes who are at high cardiovascular risk.
The decision gives one of the country’s fastest-growing diabetes drugs a major new use beyond controlling blood sugar.
Mounjaro, whose active ingredient is tirzepatide, is already widely prescribed for type 2 diabetes and is also sold under the Zepbound brand for obesity treatment.
The expanded approval is based on a large head-to-head cardiovascular trial involving more than 13,000 patients with type 2 diabetes and elevated heart risk.
In that study, patients taking Mounjaro experienced an 8% lower rate of major cardiovascular events compared with patients taking Lilly’s older diabetes drug Trulicity.
Those events included heart attack, stroke and cardiovascular death.
The result is important because people with type 2 diabetes face a substantially higher risk of cardiovascular disease, making heart protection an increasingly important part of diabetes treatment.
The approval could also influence which drugs physicians choose for higher-risk patients.
Until now, Mounjaro’s primary role was improving blood sugar control. The new cardiovascular indication gives doctors another reason to prescribe the drug to patients who are already at elevated risk of heart attack or stroke.
It could also affect insurance coverage.
Health plans often make coverage decisions based partly on a drug’s FDA-approved uses. A formal cardiovascular indication gives Lilly another argument for broader access to Mounjaro among patients with diabetes and heart disease.
Mounjaro has become one of Lilly’s biggest products.
Sales reached approximately $9.9 billion in the second quarter, up 91% from a year earlier as global demand for GLP-1 and related metabolic drugs continues to surge.
The approval also intensifies competition with Novo Nordisk, whose Wegovy and other diabetes and obesity medicines have received cardiovascular-related indications.
For patients, the significance goes beyond weight loss or blood sugar.
The competition among the major GLP-1 drugmakers is increasingly shifting toward whether these medicines can prevent some of the most serious and costly complications associated with diabetes and obesity.
With Friday’s FDA decision, Mounjaro can now officially make that claim for high-risk adults with type 2 diabetes.
JBizNews Desk | Indianapolis
© JBizNews.com All Rights Reserved. Reproduction or distribution without written permission is prohibited.